|
AU2013327136A1
(en)
|
2012-10-02 |
2015-04-16 |
Memorial Sloan-Kettering Cancer Center |
Compositions and methods for immunotherapy
|
|
AU2013204922B2
(en)
|
2012-12-20 |
2015-05-14 |
Celgene Corporation |
Chimeric antigen receptors
|
|
EP2934532B1
(en)
|
2012-12-20 |
2019-10-23 |
Purdue Research Foundation |
Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics
|
|
SG11201507026WA
(en)
*
|
2013-02-06 |
2015-10-29 |
Anthrogenesis Corp |
Modified t lymphocytes having improved specificity
|
|
DK2958943T3
(da)
|
2013-02-20 |
2019-12-09 |
Univ Pennsylvania |
Behandling af cancer ved anvendelse af humaniseret anti-EGFRvIII kimær antigenreceptor
|
|
US9944898B2
(en)
*
|
2013-03-11 |
2018-04-17 |
Case Western Reserve University |
Method of generating tumor-specific T cells
|
|
US11071754B2
(en)
|
2013-03-11 |
2021-07-27 |
Case Western Reserve University |
Method of generating tumor-specific T cells
|
|
WO2015142314A1
(en)
|
2013-03-15 |
2015-09-24 |
Memorial Sloan-Kettering Cancer Center |
Compositions and methods for immunotherapy
|
|
AU2014240083C1
(en)
|
2013-03-15 |
2019-10-24 |
Celgene Corporation |
Modified T lymphocytes
|
|
US11041021B2
(en)
|
2014-05-23 |
2021-06-22 |
University Of Florida Research Foundation, Incorporated |
Car based immunotherapy
|
|
GB201506423D0
(en)
*
|
2015-04-15 |
2015-05-27 |
Tc Biopharm Ltd |
Gamma delta T cells and uses thereof
|
|
TWI750110B
(zh)
|
2014-07-21 |
2021-12-21 |
瑞士商諾華公司 |
使用人類化抗-ｂｃｍａ嵌合抗原受體治療癌症
|
|
KR20170037625A
(ko)
|
2014-07-21 |
2017-04-04 |
노파르티스 아게 |
Cll-1 키메라 항원 수용체를 사용한 암의 치료
|
|
EP2990416B1
(en)
*
|
2014-08-29 |
2018-06-20 |
GEMoaB Monoclonals GmbH |
Universal chimeric antigen receptor expressing immune cells for targeting of diverse multiple antigens and method of manufacturing the same and use of the same for treatment of cancer, infections and autoimmune disorders
|
|
KR102376244B1
(ko)
|
2014-12-24 |
2022-03-21 |
오토러스 리미티드 |
세포
|
|
MA41433A
(fr)
|
2015-01-26 |
2017-12-05 |
Baylor College Medicine |
Cellules immunitaires universelles pour l'immunothérapie anticancéreuse
|
|
CN113713091A
(zh)
|
2015-02-06 |
2021-11-30 |
新加坡国立大学 |
工程免疫细胞及其用途和生产方法
|
|
EP3256492A4
(en)
|
2015-02-09 |
2018-07-11 |
University of Florida Research Foundation, Inc. |
Bi-specific chimeric antigen receptor and uses thereof
|
|
WO2016134284A1
(en)
*
|
2015-02-19 |
2016-08-25 |
University Of Florida Research Foundation, Inc. |
Chimeric antigen receptors and uses thereof
|
|
CA2984624A1
(en)
*
|
2015-03-18 |
2016-09-22 |
Baylor College Of Medicine |
Her2/erbb2 chimeric antigen receptor
|
|
HK1250011A1
(zh)
|
2015-03-31 |
2018-11-23 |
Sorriso Pharmaceuticals, Inc. |
具有蛋白酶可切割接头的肽构建体
|
|
WO2016156468A1
(en)
|
2015-03-31 |
2016-10-06 |
Vhsquared Limited |
Polypeptides
|
|
MX2017012939A
(es)
|
2015-04-08 |
2018-05-22 |
Novartis Ag |
Terapias cd20, terapias cd22 y terapias de combinacion con una celula que expresa un receptor quimerico de antigeno (car) de cd19.
|
|
GB201507368D0
(en)
|
2015-04-30 |
2015-06-17 |
Ucl Business Plc |
Cell
|
|
CN107995913B
(zh)
|
2015-05-18 |
2022-02-11 |
T细胞受体治疗公司 |
使用融合蛋白对tcr重编程的组合物和方法
|
|
TWI833684B
(zh)
*
|
2015-06-25 |
2024-03-01 |
美商生物細胞基因治療有限公司 |
嵌合抗原受體（ｃａｒ）、組合物及其使用方法
|
|
GB201513540D0
(en)
|
2015-07-31 |
2015-09-16 |
King S College London |
Therapeutic agents
|
|
CA2999037A1
(en)
|
2015-09-23 |
2017-03-30 |
Cytoimmune Therapeutics, LLC |
Flt3 directed car cells for immunotherapy
|
|
US12241053B2
(en)
|
2015-10-09 |
2025-03-04 |
The Brigham And Women's Hospital, Inc. |
Modulation of novel immune checkpoint targets
|
|
GB201518816D0
(en)
|
2015-10-23 |
2015-12-09 |
Autolus Ltd |
Receptor
|
|
WO2017075451A1
(en)
|
2015-10-28 |
2017-05-04 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1
|
|
WO2017075465A1
(en)
|
2015-10-28 |
2017-05-04 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses by detecting and targeting gata3
|
|
AU2016355178B9
(en)
|
2015-11-19 |
2019-05-30 |
Massachusetts Institute Of Technology |
Lymphocyte antigen CD5-like (CD5L)-interleukin 12B (p40) heterodimers in immunity
|
|
ES2875747T3
(es)
*
|
2016-01-11 |
2021-11-11 |
Univ Leland Stanford Junior |
Proteínas quiméricas y métodos de inmunoterapia
|
|
PT3436079T
(pt)
|
2016-04-01 |
2021-10-06 |
Kite Pharma Inc |
Recetores de antigénios quiméricos e de células t e métodos de uso
|
|
KR20200068750A
(ko)
|
2016-04-01 |
2020-06-15 |
카이트 파마 인코포레이티드 |
키메라 수용체 및 그의 사용 방법
|
|
CN109414455B
(zh)
|
2016-04-01 |
2023-01-20 |
凯德药业股份有限公司 |
Bcma结合分子及其使用方法
|
|
JP7282521B2
(ja)
|
2016-04-08 |
2023-05-29 |
パーデュー・リサーチ・ファウンデイション |
Ｃａｒ ｔ細胞療法のための方法および組成物
|
|
WO2017190096A1
(en)
|
2016-04-29 |
2017-11-02 |
University Of Florida Research Foundation Incorporated |
Chimeric antigen receptors and uses thereof
|
|
EP3458485B1
(en)
*
|
2016-05-19 |
2021-12-29 |
The General Hospital Corporation |
Tethered interleukin-2 to its receptor il-2rbeta, a platform to enhance natural killer and regulatory t cell activity
|
|
JP7114490B2
(ja)
*
|
2016-06-24 |
2022-08-08 |
アイセル・ジーン・セラピューティクス・エルエルシー |
キメラ抗体受容体（ＣＡＲｓ）の構成およびその使用方法
|
|
EP3494138A1
(en)
|
2016-08-02 |
2019-06-12 |
TCR2 Therapeutics Inc. |
Compositions and methods for tcr reprogramming using fusion proteins
|
|
US20190262399A1
(en)
|
2016-09-07 |
2019-08-29 |
The Broad Institute, Inc. |
Compositions and methods for evaluating and modulating immune responses
|
|
CN106635998B
(zh)
*
|
2016-09-14 |
2018-01-09 |
深圳市默赛尔生物医学科技发展有限公司 |
抗体调控的双抗原特异性t细胞及其制备方法和应用
|
|
CA3036745A1
(en)
|
2016-10-07 |
2018-04-12 |
TCR2 Therapeutics Inc. |
Compositions and methods for t-cell receptors reprogramming using fusion proteins
|
|
US12447213B2
(en)
|
2016-10-07 |
2025-10-21 |
The Broad Institute, Inc. |
Modulation of novel immune checkpoint targets
|
|
WO2018075820A2
(en)
|
2016-10-20 |
2018-04-26 |
Celgene Corporation |
Cereblon-based heterodimerizable chimeric antigen receptors
|
|
WO2018089386A1
(en)
|
2016-11-11 |
2018-05-17 |
The Broad Institute, Inc. |
Modulation of intestinal epithelial cell differentiation, maintenance and/or function through t cell action
|
|
SG11201903830TA
(en)
|
2016-11-22 |
2019-05-30 |
Nat Univ Singapore |
Blockade of cd7 expression and chimeric antigen receptors for immunotherapy of t-cell malignancies
|
|
US11851491B2
(en)
|
2016-11-22 |
2023-12-26 |
TCR2 Therapeutics Inc. |
Compositions and methods for TCR reprogramming using fusion proteins
|
|
JP7178355B2
(ja)
|
2017-02-28 |
2022-11-25 |
エンドサイト・インコーポレイテッド |
Ｃａｒ ｔ細胞療法のための組成物および方法
|
|
WO2018183908A1
(en)
|
2017-03-31 |
2018-10-04 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for treating ovarian tumors
|
|
EP3606518A4
(en)
|
2017-04-01 |
2021-04-07 |
The Broad Institute, Inc. |
METHODS AND COMPOSITIONS FOR DETECTION AND MODULATION OF IMMUNOTHERAPY RESISTANCE GENE SIGNATURE IN CANCER
|
|
US20200071773A1
(en)
|
2017-04-12 |
2020-03-05 |
Massachusetts Eye And Ear Infirmary |
Tumor signature for metastasis, compositions of matter methods of use thereof
|
|
WO2018191558A1
(en)
|
2017-04-12 |
2018-10-18 |
The Broad Institute, Inc. |
Modulation of epithelial cell differentiation, maintenance and/or function through t cell action, and markers and methods of use thereof
|
|
WO2018195339A1
(en)
*
|
2017-04-19 |
2018-10-25 |
Board Of Regents, The University Of Texas System |
Immune cells expressing engineered antigen receptors
|
|
EP3622092A4
(en)
|
2017-05-11 |
2021-06-23 |
The Broad Institute, Inc. |
METHODS AND COMPOSITIONS OF USE OF CD8 + TUMOR-INFILTRATING LYMPHOCYTE SUBTYPES AND GENE SIGNATURES THEREOF
|
|
CN107267555B
(zh)
*
|
2017-05-27 |
2020-03-20 |
上海优卡迪生物医药科技有限公司 |
一种基于octs技术的恶性胶质瘤car-t治疗载体及其构建方法和应用
|
|
WO2018232195A1
(en)
|
2017-06-14 |
2018-12-20 |
The Broad Institute, Inc. |
Compositions and methods targeting complement component 3 for inhibiting tumor growth
|
|
CA3287539A1
(en)
|
2017-06-21 |
2026-03-02 |
Icell Gene Therapeutics Llc |
CHIMERIC ANTIGEN RECEPTORS (CARs), COMPOSITIONS AND METHODS THEREOF
|
|
US12049643B2
(en)
|
2017-07-14 |
2024-07-30 |
The Broad Institute, Inc. |
Methods and compositions for modulating cytotoxic lymphocyte activity
|
|
US20190038733A1
(en)
|
2017-08-10 |
2019-02-07 |
National University Of Singapore |
T cell receptor-deficient chimeric antigen receptor t-cells and methods of use thereof
|
|
CN109503715B
(zh)
*
|
2017-09-15 |
2023-12-15 |
科济生物医药（上海）有限公司 |
Il-4r的融合蛋白及其应用
|
|
EP3695408B1
(en)
|
2017-10-02 |
2026-01-21 |
The Broad Institute, Inc. |
Medical use of cdk4/6- and checkpoint-inhibitors in phased combination, in treatment of cancer
|
|
WO2019084055A1
(en)
|
2017-10-23 |
2019-05-02 |
Massachusetts Institute Of Technology |
CLASSIFICATION OF GENETIC VARIATION FROM UNICELLULAR TRANSCRIPTOMS
|
|
EP3710039A4
(en)
|
2017-11-13 |
2021-08-04 |
The Broad Institute, Inc. |
METHODS AND COMPOSITIONS FOR TREATMENT OF CANCER BY TARGETING THE CLEC2D-KLRB1 PATH
|
|
WO2019094955A1
(en)
|
2017-11-13 |
2019-05-16 |
The Broad Institute, Inc. |
Methods and compositions for targeting developmental and oncogenic programs in h3k27m gliomas
|
|
CN109988242A
(zh)
*
|
2018-01-02 |
2019-07-09 |
武汉波睿达生物科技有限公司 |
联合嵌合抗原受体、表达载体、慢病毒及t细胞
|
|
US11994512B2
(en)
|
2018-01-04 |
2024-05-28 |
Massachusetts Institute Of Technology |
Single-cell genomic methods to generate ex vivo cell systems that recapitulate in vivo biology with improved fidelity
|
|
CN108220238A
(zh)
*
|
2018-01-09 |
2018-06-29 |
郑州大学第附属医院 |
一种减少cd8+t细胞凋亡并增强其功能的培养方法
|
|
JP7549303B2
(ja)
|
2018-01-22 |
2024-09-11 |
エンドサイト・インコーポレイテッド |
Ｃａｒ ｔ細胞の使用方法
|
|
JP7273421B2
(ja)
|
2018-02-21 |
2023-05-15 |
ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム |
ナチュラルキラー細胞の活性化および拡大のための方法ならびにその使用
|
|
CN112105382A
(zh)
|
2018-02-23 |
2020-12-18 |
恩多塞特公司 |
用于car t细胞疗法的顺序方法
|
|
CA3092794A1
(en)
|
2018-03-01 |
2019-09-06 |
University Of Kansas |
Techniques for generating cell-based therapeutics using recombinant t cell receptor genes
|
|
US11957695B2
(en)
|
2018-04-26 |
2024-04-16 |
The Broad Institute, Inc. |
Methods and compositions targeting glucocorticoid signaling for modulating immune responses
|
|
KR20210008408A
(ko)
|
2018-05-23 |
2021-01-21 |
싱가포르국립대학교 |
T-세포 악성 종양의 면역요법을 위한 cd2 표면 발현 및 키메라 항원 수용체의 발현에 대한 차단
|
|
US20210371932A1
(en)
|
2018-06-01 |
2021-12-02 |
Massachusetts Institute Of Technology |
Methods and compositions for detecting and modulating microenvironment gene signatures from the csf of metastasis patients
|
|
WO2019240934A1
(en)
|
2018-06-12 |
2019-12-19 |
Promab Biotechnologies, Inc. |
Plap-car-effector cells
|
|
CA3100724A1
(en)
|
2018-06-13 |
2019-12-19 |
Novartis Ag |
B-cell maturation antigen protein (bcma) chimeric antigen receptors and uses thereof
|
|
US12036240B2
(en)
|
2018-06-14 |
2024-07-16 |
The Broad Institute, Inc. |
Compositions and methods targeting complement component 3 for inhibiting tumor growth
|
|
BR112020025764A2
(pt)
|
2018-06-19 |
2021-05-11 |
Biontech Us Inc. |
neoantígenos e usos dos mesmos
|
|
US20210322473A1
(en)
*
|
2018-07-18 |
2021-10-21 |
The General Hospital Corporation |
Modified t cells and methods of their use
|
|
EP3829312A4
(en)
*
|
2018-08-04 |
2022-07-06 |
Abcyte Therapeutics Inc. |
MULTIFUNCTIONAL AND MULTI-TARGETING CAR SYSTEM AND METHODS OF USE
|
|
WO2020072700A1
(en)
|
2018-10-02 |
2020-04-09 |
Dana-Farber Cancer Institute, Inc. |
Hla single allele lines
|
|
US20210379057A1
(en)
|
2018-10-16 |
2021-12-09 |
Massachusetts Institute Of Technology |
Nutlin-3a for use in treating a mycobacterium tuberculosis infection
|
|
WO2020131586A2
(en)
|
2018-12-17 |
2020-06-25 |
The Broad Institute, Inc. |
Methods for identifying neoantigens
|
|
US11739156B2
(en)
|
2019-01-06 |
2023-08-29 |
The Broad Institute, Inc. Massachusetts Institute of Technology |
Methods and compositions for overcoming immunosuppression
|
|
WO2020186101A1
(en)
|
2019-03-12 |
2020-09-17 |
The Broad Institute, Inc. |
Detection means, compositions and methods for modulating synovial sarcoma cells
|
|
US20220142948A1
(en)
|
2019-03-18 |
2022-05-12 |
The Broad Institute, Inc. |
Compositions and methods for modulating metabolic regulators of t cell pathogenicity
|
|
EP3959307A4
(en)
*
|
2019-04-22 |
2023-08-23 |
Nanjing Legend Biotech Co., Ltd. |
Engineered cells and uses thereof
|
|
US20220235340A1
(en)
|
2019-05-20 |
2022-07-28 |
The Broad Institute, Inc. |
Novel crispr-cas systems and uses thereof
|
|
US20220226464A1
(en)
|
2019-05-28 |
2022-07-21 |
Massachusetts Institute Of Technology |
Methods and compositions for modulating immune responses
|
|
WO2020254827A1
(en)
|
2019-06-21 |
2020-12-24 |
Vhsquared Limited |
Polypeptides
|
|
JP7680377B2
(ja)
|
2019-06-21 |
2025-05-20 |
ソリッソ ファーマシューティカルズ，インク． |
ポリペプチド
|
|
KR20220063148A
(ko)
|
2019-06-21 |
2022-05-17 |
소리소 파마슈티컬스 인크. |
조성물
|
|
WO2021030627A1
(en)
|
2019-08-13 |
2021-02-18 |
The General Hospital Corporation |
Methods for predicting outcomes of checkpoint inhibition and treatment thereof
|
|
US12421557B2
(en)
|
2019-08-16 |
2025-09-23 |
The Broad Institute, Inc. |
Methods for predicting outcomes and treating colorectal cancer using a cell atlas
|
|
WO2021041922A1
(en)
|
2019-08-30 |
2021-03-04 |
The Broad Institute, Inc. |
Crispr-associated mu transposase systems
|
|
US12297426B2
(en)
|
2019-10-01 |
2025-05-13 |
The Broad Institute, Inc. |
DNA damage response signature guided rational design of CRISPR-based systems and therapies
|
|
US12394502B2
(en)
|
2019-10-02 |
2025-08-19 |
The General Hospital Corporation |
Method for predicting HLA-binding peptides using protein structural features
|
|
US11981922B2
(en)
|
2019-10-03 |
2024-05-14 |
Dana-Farber Cancer Institute, Inc. |
Methods and compositions for the modulation of cell interactions and signaling in the tumor microenvironment
|
|
US12195725B2
(en)
|
2019-10-03 |
2025-01-14 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for modulating and detecting tissue specific TH17 cell pathogenicity
|
|
US11793787B2
(en)
|
2019-10-07 |
2023-10-24 |
The Broad Institute, Inc. |
Methods and compositions for enhancing anti-tumor immunity by targeting steroidogenesis
|
|
US11844800B2
(en)
|
2019-10-30 |
2023-12-19 |
Massachusetts Institute Of Technology |
Methods and compositions for predicting and preventing relapse of acute lymphoblastic leukemia
|
|
IL292924A
(en)
|
2019-11-26 |
2022-07-01 |
Novartis Ag |
Chimeric antigen receptors cd19 and cd22 and their uses
|
|
US12509754B2
(en)
|
2019-11-26 |
2025-12-30 |
Nippon Steel Corporation |
Hot-stamped member and steel sheet for hot stamping
|
|
US12165747B2
(en)
|
2020-01-23 |
2024-12-10 |
The Broad Institute, Inc. |
Molecular spatial mapping of metastatic tumor microenvironment
|
|
KR20230004680A
(ko)
|
2020-04-17 |
2023-01-06 |
시티 오브 호프 |
Flt3-양성 악성 종양의 치료를 위한 flt3-표적화된 키메라 항원 수용체 변형 세포
|
|
CN116249548A
(zh)
|
2020-05-11 |
2023-06-09 |
詹森生物科技公司 |
用于治疗多发性骨髓瘤的方法
|
|
AU2021308702A1
(en)
|
2020-07-17 |
2023-03-16 |
Instil Bio (Uk) Limited |
Receptors providing targeted costimulation for adoptive cell therapy
|
|
CN113201063B
(zh)
*
|
2020-07-31 |
2022-04-19 |
北京市神经外科研究所 |
IL7Rα的截短体及其在制备治疗肿瘤的药物中的用途
|
|
EP4355340A4
(en)
|
2021-06-16 |
2025-05-21 |
Instil Bio, Inc. |
RECEPTORS FOR TARGETED COSTIMULATION FOR ADOPTIVE CELL THERAPY
|
|
EP4370213A4
(en)
|
2021-07-16 |
2025-06-04 |
Instil Bio (Uk) Limited |
Chimeric molecules for targeted costimulation for adoptive cell therapy
|
|
AU2022366987A1
(en)
|
2021-10-14 |
2024-05-16 |
Arsenal Biosciences, Inc. |
Immune cells having co-expressed shrnas and logic gate systems
|
|
IL312503A
(en)
|
2021-11-03 |
2024-07-01 |
Janssen Biotech Inc |
Methods of treating cancers and enhancing efficacy of bcmaxcd3 bispecific antibodies
|
|
WO2024077256A1
(en)
|
2022-10-07 |
2024-04-11 |
The General Hospital Corporation |
Methods and compositions for high-throughput discovery ofpeptide-mhc targeting binding proteins
|
|
CN117567637A
(zh)
*
|
2022-10-11 |
2024-02-20 |
四川大学华西医院 |
一种用于靶向肿瘤微环境的信号感受器和用于靶向治疗肿瘤的细胞
|
|
WO2024124044A1
(en)
|
2022-12-07 |
2024-06-13 |
The Brigham And Women’S Hospital, Inc. |
Compositions and methods targeting sat1 for enhancing anti¬ tumor immunity during tumor progression
|
|
CN116178538B
(zh)
*
|
2023-01-05 |
2024-08-02 |
暨南大学 |
靶向热休克蛋白70的纳米抗体及其制备方法与应用
|
|
WO2025059533A1
(en)
|
2023-09-13 |
2025-03-20 |
The Broad Institute, Inc. |
Crispr enzymes and systems
|
|
WO2025072372A1
(en)
*
|
2023-09-26 |
2025-04-03 |
The General Hospital Corporation |
Car-t cells expressing vegf binding proteins
|
|
WO2025097055A2
(en)
|
2023-11-02 |
2025-05-08 |
The Broad Institute, Inc. |
Compositions and methods of use of t cells in immunotherapy
|
|
WO2025117544A1
(en)
|
2023-11-29 |
2025-06-05 |
The Broad Institute, Inc. |
Engineered omega guide molecule and iscb compositions, systems, and methods of use thereof
|